Satsuma Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Satsuma Pharmaceuticals, Inc. | STSA - NASDAQ |
$14.00-$16.00 | $15.00 | $19.00 | 5.5 million | 9/13/2019 |
| Credit Suisse, SVB Leerink, Evercore | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-08-16 Terms Added 2019-09-03 | ||||||
Satsuma Pharmaceuticals, Inc. Quote & Chart - Click for current quote - STSA
IPO Boutique aggregates information on public companies and private companies, such as "STSA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Satsuma Pharmaceuticals, Inc. (adapted from Satsuma Pharmaceuticals, Inc. prospectus):
They are a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "STSA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.